Rise and shine. Another busy day is on the way, especially with the US Supreme Court ruling this morning on the Affordable Care Act. To brace ourselves, we are downing a few cups of stimulation. Why wait, you know? Meanwhile, we are keeping occupied with other matters, such as a webinar on the timely topic of healthcare payers and players, which takes place at 1 pm ET today (
take a peek). We invite you to join us. For now, we will dig in to our to-do list. As for you, here are some tidbits. Have a great day and stay in touch...Vertex Shares Plunge Due To Unclear Study Data (Bloomberg News)
Gilead Seeks FDA Approval For HIV Drug (San Francisco Business Times)
Purdue Tussles Over OxyContin Exclusivity (Wall Street Journal)
Shionogi Says FDA Is Reviewing Dry Vagina Drug (Pharma Times)
Asthma Drugs Do Not Cause Excess Suicide Risk: Study (Reuters)
Vertex Offers More Evidence For Cystic Fibrosis Drug (TheStreet)
Shire Gaucher Drugs Beats Sanofi Med In Trial (Reuters)
Glaxo CEO Says Europe Is Much Worse Than Expected (Bloomberg News)
FDA Looks To Control Mobile Apps Market (Kaiser Health News)
Shamrock Gets FDA Warning For Mislabeling Drug Strength (Outsourcing Pharma)
Health Canada Warns Hospira Over Paclitaxel Batches (InPharma Technologist)
FDA Grants Priority Review To Bayer Colorectal Cancer Drug (Reuters)
EDITOR'S NOTE: Please check this post for updates during the day
Supreme Court pic thx to Rob Crawley on flickr






6 Comments
"The 119 investors surveyed, on average, expected to see a 6.7% improvement in placebo-adjusted lung function from the high dose VX-809 arm of the study. This is precisely what Vertex delivered."
Traditionally the delta for designing the Phase III study (expected degree of improvement) is predicted by the Medical Director of the pharma company based on Phase II data and other avaible evidence without any outside help. He/she then sits down with the biostatistician who provides the required sample size based on the anticipated delta, the desired Power (usually set at 80-90%), with the significance level usually set to 0.05 for efficacy. From there the sample size goes into the protocol and the study proceeds.
It seems now that The Street is telling the company what the delta should be in order for the drug to make a splash. The logical next step to me is to have the guys from Morgan, Goldman Sachs, et al actually sit on the Protocol Development Committee instead of seeking outside input. Would be a great time saver, IMO.
A little dab will do ya!
http://www.cfgenetherapy.org.uk/publications/daviesnacfc2011.html
You mean this "Street"? The ideology whose DOGma consists of a nihilistic "wholesale rejection of empirical observable facts"? Talk about IMAGINARY metrics for the bench scientists! Always set up to FAIL....
Cut and pasted:
“The crowning achievement of the academics who devised modern free market fundamentalist ideology was the wholesale rejection of empirical observable facts . One of the most extreme permutations of this school of thought, The Austrian School of Economics, even rejects the scientific method. You can’t make this stuff up!
Instead of facts, they embrace false “axiom” systems, which are basically unsubstantiated opinions on human nature that are treated as though they were empirical facts in order to guide their ideas. That’s why most mainstream economists don’t take the Austrian School Seriously, even though a less extreme forms (like the Chicago School of Economics, which inspired a US-backed military dictatorship in Chile) have dominated US Economic policy & global economic development for the past 30 years.”